RD
Rajendra Dhruva Patil
Executive
Other
Browse the detailed record of transactions filed by Rajendra Dhruva Patil, Executive. Officer active across 1 company, notably Syngene International Limited. In total, 15 disclosures have been logged. Activity tracked since 2 September 2021. The latest transaction was disclosed on 13 August 2024 (Sale). Regulator: SEBI (PIT + SAST). All data is openly available.
Companies and markets linked to Rajendra Dhruva Patil
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations15 total
8,500 shares@ ₹825.166.8% of flowEquity SharesSEBI:c671ec9a23b2964df1d738efc8a53fba45f55b07
20,743 shares@ ₹816.4016.4% of flowEquity SharesSEBI:272fa38657b7db27d13f8a370f370682c22b15e9
1,500 shares@ ₹853.33331.3% of flowEquity SharesSEBI:b432ef9aa2b0cf15b9d668ba9331b5e6d6ddf20b
23,049 shares@ ₹809.7018.6% of flowEquity SharesSEBI:d373af0c6bbd717853ccc52eb14078b12596a1d8
9,350 shares@ ₹795.247.4% of flowEquity SharesSEBI:772d9d3716d79bd1fe650c789a3931e4896688cd
1,000 shares@ ₹710.000.7% of flowEquity SharesSEBI:931ff2cf7855305029fcfd186671cf2426cfc744
1,000 shares@ ₹705.000.7% of flowEquity SharesSEBI:c38a0ba42cf17d4a9688c6f131599ee69a46b3d9
4,000 shares@ ₹587.9572.4% of flowEquity SharesSEBI:15609d81ad8a1b56aecfe0d04dfae3c64b2e53dc
23,048 shares@ ₹562.0014.5% of flowEquity SharesSEBI:2b1429f345377d9d601ef9489fb70c9d4045dabf
8,800 shares@ ₹560.005.5% of flowEquity SharesSEBI:3de8e19a7b2de54e56e74cbd50018a12c47025ee
2,500 shares@ ₹605.001.7% of flowEquity SharesSEBI:2e398729604f4fd3f70e6032ea87875b036dbc3a
4,900 shares@ ₹649.79593.3% of flowEquity SharesSEBI:76ab042ee11f34cbdcb746eeecfca248d2edf1a3
100 shares@ ₹625.000.1% of flowEquity SharesSEBI:9100bb0290706a5be454f7f84fe80a1103db00ed
8,600 shares@ ₹633.36020.0000% mcap27.1% of flowEquity SharesSEBI:07797caecfdd1f2725c229c6085fd4c0134b9805
23,049 shares@ ₹636.430.0001% mcap72.9% of flowEquity SharesSEBI:9de38e9277352a4dcce64880bcf0aa1de3f0b3bf
About Rajendra Dhruva Patil
RAJENDRA DHRUVA PATIL is an executive at Syngene International Limited, a company specializing in pharmaceutical research and development. With expertise in management and product development, he contributes to the innovation and growth of the company. Syngene International is recognized for its high-quality research solutions.